Clincosm LogoSign in Get a demo

Serum Lipids and Glucose Levels in Relation to CVD Outcomes in Patients With Ischemic Heart Failure

Sponsor
Guangdong Provincial People's Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT03206593
Collaborator
(none)
2,000
Enrollment
1
Location
48
Anticipated Duration (Months)
41.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Current prospective cohort study is to evaluate the association between fasting lipid profiles (including total cholesterol, low density lipoprotein-cholesterol, high density lipoprotein-cholesterol, triglycerides, apolipoprotein A, apolipoprotein B and lipoprotein(a)) and fasting plasma glucose at admission with cardiovascular disease outcomes (including fatal and non-fatal myocardial infarction, fatal and non-fatal ischemic stroke, re-hospitalization due to heart failure, revascularization by percutaneous coronary intervention or coronary artery bypass grafting, or cardiovascular mortality) and all-cause mortality.in patients with ischemic heart failure and left ventricular ejection fraction < 45 % evaluated by echocardiography during 12 months follow-up.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    2000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Fasting Serum Lipids and Glucose Levels in Relation to CVD Outcomes in Patients With Ischemic Heart Failure
    Actual Study Start Date :
    Jan 1, 2016
    Anticipated Primary Completion Date :
    Dec 31, 2018
    Anticipated Study Completion Date :
    Dec 31, 2019

    Outcome Measures

    Primary Outcome Measures

    1. Cardiovascular diseases outcomes [12 months after discharge from index hospitalization]

      Fatal or non-fatal myocardial infarction, fatal or non-fatal ischemic stroke, re-hospitalization due to heart failure, revascularization by percutaneous coronary intervention or coronary artery bypass grafting, and cardiovascular mortality

    Secondary Outcome Measures

    1. All-cause mortality [12 months after discharge from index hospitalization]

      All-cause mortality

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria: 1.Diagnosed as coronary artery disease by coronary angiography; 2. Left ventricular ejection fraction < 45% evaluated by echocardiography during index hospitalization.

    -

    Exclusion Criteria: Coexistent malignant diseases; stage 3 or more of chronic kidney disease; liver dysfunction with ALT or AST higher than 3 times of normal limit range; do not want to participant in current study

    -

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Guangdong General Hospital Guangzhou Guangdong China 510080

    Sponsors and Collaborators

    • Guangdong Provincial People's Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Faye Jiang, Dr., Guangdong Provincial People's Hospital
    ClinicalTrials.gov Identifier:
    NCT03206593
    Other Study ID Numbers:
    • No.GDREC2017128H(R1)
    First Posted:
    Jul 2, 2017
    Last Update Posted:
    Jul 2, 2017
    Last Verified:
    Jun 1, 2017
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Heart Failure
    Ischemia

    Study Results

    No Results Posted as of Jul 2, 2017